GlobalData on MSN13h
Shionogi’s RSV antiviral reduces viral load in Phase II human challenge trial
Shionogi’s oral antiviral for respiratory syncytial virus (RSV) has met its primary endpoint in a Phase II study that saw ...
The American Journal of Managed Care13h
Resveratrol Oral Supplement Associated With Lower Rates of Intravitreal Aflibercept Injections
Lower rates of both progression of macular fibrosis and intravitreal aflibercept injections were found in those who used the ...
FierceBiotech17h
Shionogi's RSV antiviral reduces viral load in phase 2 trial of adults
Shionogi’s respiratory syncytial virus (RSV) antiviral for adults has proven its ability to reduce viral load in a phase 2 ...